Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3520-3525

  Ritland, Steve R ^a   Rowse, Gerald J ^a   Chang, Yue ^a   Gendler, Sandra J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CHROMOSOME 4; CHROMOSOME LOSS; CONTROLLED STUDY; FEMALE; GENE LOCUS; HETEROZYGOSITY LOSS; LUNG METASTASIS; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; CHROMOSOME DELETION; CHROMOSOME MAPPING; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MICROSATELLITE REPEATS; SPECIES SPECIFICITY; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 0030873520     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ponder, B. A. J., Cavanee, W. K., and Solomon, E. Genetics and Cancer: A Second Look, pp. 1-397. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1995.
2. Muthuswamy, S. K., and Muller, W. J. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene, 11: 271-279, 1995.
3. Amundadottir, L. T., Johnson, M. D., Merlino, G., Smith, G. H., and Dickson, R. B. Synergistic interaction of transforming growth factor α and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth & Differ., 6: 737-748, 1995.
4. Adams, J. M., and Cory, S. Oncogene co-operation in leukaemogenesis. Cancer Surv., 15: 119-141, 1992.
5. Kemp, C. J., Fee, F., and Balmain, A. Allelotype analysis of mouse skin tumors using polymorphic microsatellites: sequential genetic alterations on chromosomes 6, 7, and 11. Cancer Res., 53: 6022-6027, 1993.
6. Davis, L. M., Caspary, W. J., Sakallah, S. A., Maronpot, R., Wiseman, R., Barret, J. C., Elliot, R., and Hozier, J. C. Loss of heterozygosily in spontaneous and chemically induced tumors of the B6C3F1 mouse. Carcinogenesis (Lond.), 15: 1637-1645, 1994.
7. Hegi, M. E., Devereux, T. R., Dietrich, W. F., Cochran, C. J., Lander, E. S., Foley, J. F., Maronpot, R. R., Anderson, M. W., and Wiseman, R. W. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res., 54: 6257-6264, 1994.
8. Herzog, C. R., Wiseman, R. W., and You, M. Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors. Cancer Res., 54: 4007-4010, 1994.
9. Wiseman, R. W., Cochran, C., Dietrich, W., Lander, E. S., and Soderkvist, P. Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumorsuppressor genes. Proc. Nat. Acad. Sci. USA, 91: 3759-3763, 1994.
10. Dudley, M. E., Sundberg, J. P., and Roopenian, D. C. Motif-primed polymerase chain reaction-based allelotype of sarcomas induced by 3-methylcholanthrene in interspecific hybrid mice. Oncogene, 11: 517-524, 1995.
11. Zhuang, S-M., Eklund, L. K., Cochran, C., Rao, G. N., Wiseman, R. W., and Soderkvist, P. Allelotype analysis of 2′,3′-dideoxycytidine-and 1,3-butadieneinduced lymphomas in B6C3F1 mice. Cancer Res., 56: 3338-3343, 1996.
12. Dietrich, W. F., Radany, E. H., Smith, J. S., Bishop, J. M., Hanahan, D., and Lander, E. S. Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes of chromosomes 9 and 16. Proc. Natl. Acad. Sci. USA, 91: 9451-9455, 1994.
13. + in intestinal adenomas from Min mice. Cancer Res., 54: 5947-5952, 1994.
14. Parangi, S., Dietrich, W., Christofori, G., Lander, S., and Hanahan, D. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res., 55: 6071-6076, 1995.
15. Guy, C. T., Cardiff, R. D., and Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T Oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol., 12: 954-961, 1992.
16. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-10582, 1992.
17. Bolen, J. B., Theile, C. J., Israel, M. A., Yonemoto, W., Lipsich, L. A., and Brugge, J. S. Enhancement of cellular src gene product-associated tyrosine kinase activity following polyomavirus infection and transformation. Cell, 38: 767-777, 1984.
18. Kornbluth, S., Sudul, M., and Hanafusa, H. Association of the polyomavirus middle T antigen with the c-yes protein. Nature (Lond.), 325: 171-173, 1986.
19. Kypta, R. M., Hemming, M. A., and Courtneidge, S. A. Identification and characterization of p59 fyn (a src-like protein kinase) in normal and polyoma virus transformed cells. EMBO J., 7: 3837-3844, 1988.
20. Talmage, D. A., Freund, R., Young, A. T., Dahl, J., Dawe, C. J., and Benjamin, T. L. Phosphorylation of middle T by pp60 c-src: a switch for binding of phosphatidylinositol 3-kinase and optimal tumorigenesis. Cell, 59: 55-65, 1989.
21. Bargman, C. I., Hung, M-C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond.), 319: 226-230, 1986.
22. King, C. R., Kraus, M. H., and Aaronson, S. A. Amplification of a novel v-erbB related gene in human mammary carcinoma. Science (Washington DC), 229: 974-976, 1985.
23. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of Her-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
24. Gullick, W. J., Love, S. B., Wright, C., Barnes, D. M., Gutterson, B., Harris, A. L., and Altman, D. G. c-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J. Cancer, 63: 434-438, 1991.
25. Siegel, P. M., Dankfort, D. L., Hardy, W. R., and Muller, W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol., 14: 7068-7077, 1994.
26. Muthuswamy, S. K., Siegel, P. M., Dankfort, M. A., and Muller, W. J. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell. Biol., 14: 735-743, 1994.
27. Guy, C. T., Muthuswamy, S. K., Cardiff, R. D., Soriano, P., and Muller, W. J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev., 8: 23-32, 1994.
28. Jakuhczak, J. L., Merlino, G., French, J. E., Muller, W. J., Paul, B., Adhva, S., and Garges, S. Analysis of genetic instability during mammary progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc. Nat. Acad. Sci. USA, 93: 9073-9078, 1996.
29. Siegel, P. M., and Muller, W. J. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc. Nat. Acad. Sci. USA, 93: 8878-8883, 1996.
30. Bieche, I., and Lidereau, R. Genetic alterations in breast cancer. Genes Chromosomes Cancer, 14: 227-251, 1995.
31. Nagai, H., Negrini, M., Carter, S. L., Gillum, D. R., Rosenberg, A. L., Schwartz, G. F., and Croce, C M. Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res., 55: 1732-1757, 1995.
32. Bieche, I., Champeme, M. H., and Lidereau, R. A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. Cancer Res., 54: 4274-4276, 1994.
33. Bieche, I., Champeme, M. H., Matifas, F., Cropp, C. S., Callahan, R., and Lidereau, R. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res., 53: 1990-1994, 1993.
34. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylalion in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
35. Geradts, J., and Wilson, P. A. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am. J. Pathol., 146: 15-20, 1996.
36. Biggs, J. R., and Kraft, A. S Inhibitors of cyclin-dependent kinase and cancer. J. Mol. Med., 73: 509-514, 1995.
37. Miyasaka, K., Fukui, T., and Kitaguwa, T. Allelotype analysis in mouse hepatocellular carcinomas: frequent homozygous deletion of mouse homolog of p16/CDKN2 gene on chromosome 4 in culture. Biol. Pharmaceut. Bull., 19: 683-691, 1996.
38. Belinsky, S. A., Swafford, D. S., Middleton, S. K., Kennedy, C. H., and Tesfaigzi, J. Deletion and differential expression of p16INK4a in mouse lung tumors. Carcinogenesis (Lond.), 18: 115-120, 1997.
39. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 1993-1000, 1995.
40. Herman, J. G., Jen, J., Merlo, A., and Baylin, S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res., 56: 722-727, 1996.
41. Quelle, D. E., Ashmun, R. A., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., and Serrano, M. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene, 11: 635-645, 1995.
42. Dietrich, W. F., Lander, E. S., Smith, J. S., Moser, A. R., Gould, K. A., Luongo, C., Borenstein, N., and Dove, W. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell, 75: 631-639, 1993.
43. MacPhee, M., Chepenik, K. P., Liddell, R. A., Nelson, K. K., Siracusa, L. D., and Buchberg, A. M. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell, 81: 957-966, 1995.
44. Yamashita, J., Ogawa, M., and Sakai, K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery, 117: 601-608, 1995.
45. Yamashita, S., Yumashita, J., and Ogawa, M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br. J. Cancer, 69: 1166-1170, 1994.